The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
 
Van K. Morris
Honoraria - Projects in Knowledge
Consulting or Advisory Role - Array Biopharma; Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Samuel A. Jacobs
Employment - Exact Sciences
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
 
Atif Iqbal
No Relationships to Disclose
 
Patrick M Boland
Consulting or Advisory Role - Bayer
Research Funding - Abbvie (Inst); Athenex (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Ipsen (Inst); Merck (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Array BioPharma; Bayer; Lilly; Pfizer; Promega
Research Funding - Bayer; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Millennium (Inst); Revolution Medicines (Inst)
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Howard John Lim
Honoraria - Amgen; BMS Canada; Eisai; Ipsen; Merck; Roche Canada; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Taiho Pharmaceutical
 
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Norman Wolmark
No Relationships to Disclose
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)